Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.
Burmeister T, Bartels G, Gröger D, Trautmann H, Schwartz S, Lenz K, Tietze-Bürger C, Viardot A, Wäsch R, Horst HA, Reinhardt R, Gökbuget N, Hoelzer D, Kneba M, Brüggemann M. Burmeister T, et al. Among authors: kneba m. Haematologica. 2014 Feb;99(2):e23-5. doi: 10.3324/haematol.2013.090720. Haematologica. 2014. PMID: 24497567 Free PMC article. Clinical Trial. No abstract available.
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.
Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, Lüschen S, Pott C, Ritgen M, Scheuring U, Horst HA, Thiel E, Hoelzer D, Bartram CR, Kneba M; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Brüggemann M, et al. Among authors: kneba m. Blood. 2006 Feb 1;107(3):1116-23. doi: 10.1182/blood-2005-07-2708. Epub 2005 Sep 29. Blood. 2006. PMID: 16195338 Free article. Clinical Trial.
Risk-adapted treatment according to minimal residual disease in adult ALL.
Gökbuget N, Kneba M, Raff T, Bruggemann M, Scheuring U, Reutzel R, Hoelzer D. Gökbuget N, et al. Among authors: kneba m. Best Pract Res Clin Haematol. 2002 Dec;15(4):639-52. doi: 10.1053/beha.2002.0229. Best Pract Res Clin Haematol. 2002. PMID: 12617868 Review.
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.
Raff T, Gökbuget N, Lüschen S, Reutzel R, Ritgen M, Irmer S, Böttcher S, Horst HA, Kneba M, Hoelzer D, Brüggemann M; GMALL Study Group. Raff T, et al. Among authors: kneba m. Blood. 2007 Feb 1;109(3):910-5. doi: 10.1182/blood-2006-07-037093. Epub 2006 Oct 5. Blood. 2007. PMID: 17023577 Free article. Clinical Trial.
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.
Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, Fietkau R, Freund M, Ganser A, Ludwig WD, Maschmeyer G, Rieder H, Schwartz S, Serve H, Thiel E, Brüggemann M, Hoelzer D; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Gökbuget N, et al. Among authors: kneba m. Blood. 2012 Aug 30;120(9):1868-76. doi: 10.1182/blood-2011-09-377713. Epub 2012 Mar 22. Blood. 2012. PMID: 22442346 Free article. Clinical Trial.
281 results